DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Otros (Other)
Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia
Dyskinesia or abnormal involuntary movement is an unfortunate consequence of long-term therapy with L-DOPA, a gold standard for the treatment of Parkinson’s disease (PD). L-DOPA-induced dyskinesia (LID) is affected by age of onset, duration and severity of PD, L-DOPA dose, as well as gender. The main treatment modality is reduction of L-DOPA dose. Although administration of apomorphine, amantadine, and clozapine may be helpful, more effective pharmacotherapies are urgently needed. Recent advances in our understanding of the pathophysiology of LID have led to suggestions of novel interventions. In this chapter, three classes of drugs, nicotinic receptor agonists, glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonists, and cannabinoid receptor agonists, where their effectiveness in preclinical studies has been established, will be discussed in detail., Supported in part by the Howard University College of Medicine Bridge Funds and Pilot Study Awards Program (BFPSAP) 2020–2021 (YT, RLC); Spanish Ministry of Science and Innovation (PID2019-111693RBI00) and European Union’s Horizon 2020 research and innovation program, AND-PD (grant agreement no. 848002) (RM); VIEP-BUAP 2020-2021(IDL); São Paulo State Foundation for the Support of Research (FAPESP, Brazil; Grants 2014/25029-4 and 2017/24304-0), CAPES-COFECUB Grant #848/15) (EDB); and NIH/NIEHS R01ES10563 (MA)., Peer reviewed
DOI: http://hdl.handle.net/10261/386942, https://api.elsevier.com/content/abstract/scopus_id/85153662462
HANDLE: http://hdl.handle.net/10261/386942, https://api.elsevier.com/content/abstract/scopus_id/85153662462